Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

79.06 -0.64 (-0.80%)
Streaming Delayed Price Updated: 2:15 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
At the Forefront of HIV Health and Healing in Spain: Ferran's Story
SOURCE: Gilead Sciences 
Via 3BL Media
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Hope for Haiti Kicks Off Fourth Annual Hike for Haiti Challenge Campaign to Provide Access to Education and Public Health
Feel-good global movement supported by high-profile ambassadors and brands helping to fund organization's $12M plan for school rebuilding and rehabilitation following the devastating 7.2 magnitude... 
Via Newswire.com
Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story
SOURCE: Gilead Sciences 
Via 3BL Media
Claflin University's Deeply Rooted Commitment to Social Justice
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
From Gilead Sciences, Inc.
Via Business Wire
Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Opinion: Searching for the Next Generation of Sustainable Health Care
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO
SOURCE: Gilead Sciences 
Via 3BL Media
Opinion: Why Corporate Philanthropy Must Stand Against Stigma
SOURCE: Gilead Sciences 
Via 3BL Media
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and Others
Continue reading "Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and... 
Via Get News
Opinion: Building an Inclusive World Through Sports, Art, and Culture
SOURCE: Gilead Sciences 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Keto Benefits And Benefits of Drinking Ketones.
Via Marketers Media
Congratulations to Taiyin Yang, EVP, for Being Elected to the 2022 Class of the National Academy of Engineering.
SOURCE: Gilead Sciences 
Via 3BL Media
Mark Dresser Elected First Openly-LGBTQ+ President of American Society for Clinical Pharmacology and Therapeutics
SOURCE: Gilead Sciences 
Via 3BL Media
We're Proud to Have Supported a Special Issue of Tuskegee University's Journal of Healthcare, Science, and the Humanities
SOURCE: Gilead Sciences 
Via 3BL Media
Keto Vs Low Carb – Intermittent Fasting Vegan Diet For Weight Loss Site Relaunch
Via Marketers Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)
SOURCE: Gilead Sciences 
Via 3BL Media
Understanding Hepatitis D: 4 Questions With Professor Maria Buti
SOURCE: Gilead Sciences 
Via 3BL Media
Charting a Career to Help Reduce Health Inequity: Porscha's Story
SOURCE: Gilead Sciences 
Via 3BL Media
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Invests in Research for COVID-19 Treatments for All Ages
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
From Gilead Sciences, Inc.
Via Business Wire
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
From Gilead Sciences, Inc.
Via Business Wire
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
From Gilead Sciences, Inc.
Via Business Wire
Ending HIV-Related Stigma in the Southern United States: Gina's Story
SOURCE: Gilead Sciences 
Via 3BL Media
What World Cancer Day Means to Me
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.